NASDAQ:LIXTW Lixte Biotechnology (LIXTW) Stock Price, News & Analysis $0.24 +0.00 (+1.25%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock About Lixte Biotechnology Stock (NASDAQ:LIXTW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lixte Biotechnology alerts:Sign Up Key Stats Today's Range$0.20▼$0.2850-Day Range$0.14▼$0.3352-Week Range$0.02▼$0.38Volume43,467 shsAverage Volume25,397 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lixte Biotechnology (NASDAQ:LIXTW) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. Its lead candidate, LB-100, is a first-in-class inhibitor of protein phosphatase 2A (PP2A) that has been evaluated in early-phase clinical trials across multiple tumor types. Through strategic collaborations with academic research centers and clinical investigators, the company is exploring LB-100 both as a monotherapy and in combination regimens, including with radiotherapy and chemotherapeutic agents. In addition to its lead program, Lixte maintains a preclinical pipeline of analogs and related compounds designed to broaden its oncology franchise. Preclinical studies aim to characterize the pharmacological profiles and therapeutic windows of these molecules, with the goal of advancing select candidates into human studies. Lixte leverages its expertise in medicinal chemistry, translational research and clinical trial design to progress its portfolio efficiently toward proof-of-concept milestones. Founded in 2005 and headquartered in Calgary, Alberta, Canada, Lixte operates with a lean organizational structure that maximizes resource allocation toward research and development. Its clinical development efforts span North America and Europe, working with leading cancer centers to evaluate safety and efficacy endpoints. The company is led by a management team with extensive experience in oncology drug development and regulatory strategy, and it is committed to addressing unmet medical needs through innovative small-molecule therapies.AI Generated. May Contain Errors. Read More Receive LIXTW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LIXTW Stock News HeadlinesLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential AcquisitionsSeptember 11, 2025 | finanznachrichten.deLixte Biotechnology updates treasury policy to include cryptocurrencyAugust 13, 2025 | msn.comWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.September 18 at 2:00 AM | SmartAsset (Ad)Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing RequirementsJuly 16, 2025 | finanznachrichten.deLIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing RequirementsJuly 16, 2025 | finance.yahoo.comNew Clinical Findings Published in Scientific Journal Nature Validate ...July 11, 2025 | morningstar.comMNew Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer TrialsJuly 9, 2025 | finance.yahoo.comLixte Biotechnology Closes Higher; Sees Regaining Nasdaq ComplianceJuly 3, 2025 | marketwatch.comSee More Headlines LIXTW Stock Analysis - Frequently Asked Questions How have LIXTW shares performed this year? Lixte Biotechnology's stock was trading at $0.0288 at the beginning of 2025. Since then, LIXTW stock has increased by 743.8% and is now trading at $0.2430. How do I buy shares of Lixte Biotechnology? Shares of LIXTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIXTW CIK1335105 WebN/A Phone631-830-7092FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:LIXTW) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.